HHS Ditches mRNA Vaccine Program Amidst Safety Concerns, Biotech Firms and Academic Giants Face $500M Cutback

Washington, D.C.'s biotech community is buzzing with the latest news from the U.S. Department of Health and Human Services (HHS). According to an official statement released yesterday, HHS is effectively pulling the plug on its mRNA vaccine development programs under the Biomedical Advanced Research and Development Authority (BARDA). HHS Secretary Robert F. Kennedy, Jr. noted that the decision was a response to findings that mRNA vaccines are not as protective against upper respiratory infections such as COVID-19 and influenza as once hoped.

Making a pivot in federal vaccine development strategy, the agency is canceling or de-scaling a slew of contracts with major biotech firms and academic institutions, totaling upwards of $500 million. With investments directed towards platforms with stronger safety records and transparent clinical and manufacturing data practices, as Kennedy announced, HHS is shifting its focus away from the once-celebrated mRNA technology. Affected by this decision, Emory University and Tiba Biotech saw the termination of contracts, while the work involving Luminary Labs, ModeX, and Seqirus experienced de-scoping.

Not just individual contracts, but overall initiatives are taking a hit. The pandemic-driven investments under BARDA's Rapid Response Partnership Vehicle (RRPV) and VITAL Hub saw rejections and cancellations of proposals from heavy hitters like Pfizer, Sanofi Pasteur, and Moderna. Even collaborations with the Department of Defense's Joint Program Executive Office (JPEO) are being restructured, impacting a range of nucleic acid-based vaccine projects, as detailed by the U.S. Department of Health and Human Services

However, it's not a complete shutdown; some late-stage ventures, such as those with Arcturus and Amplitude will continue until completion to avoid nullifying previous taxpayer investment. In these cases, given significant prior expenditures, letting the final stages of development proceed exhibits a facet of fiscal responsibility while halting any new ventures into the mRNA space. BARDA Ventures, under the management of Global Health Investment Corporation (GHIC), was also instructed to end all mRNA vaccine-related equity investments.

Secretary Kennedy made the government's position clear: "Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them. That's why we're moving beyond the limitations of mRNA and investing in better solutions," emphasizing the department's commitment to pursue other vaccine strategies. This marks a significant shift away from what was once the forefront of the country's response to infectious diseases, as noted by the U.S. Department of Health and Human Services